Drug intelligence / Profile preview

Atorgar-CV

Development stage
Phase 4
Lead developer
Apgar
Modality
Small Molecules
Administration
Oral
01

Overview

Atorgar-CV is a fixed-dose combination pharmaceutical product developed and manufactured by Apgar Pharmaceuticals for the management of cardiovascular diseases. It consists of two primary active ingredients: atorvastatin and clopidogrel. Atorvastatin is a lipid-lowering agent belonging to the statin class, which inhibits HMG-CoA reductase to reduce cholesterol biosynthesis and lower LDL levels. Clopidogrel is a thienopyridine-class antiplatelet medication that irreversibly inhibits platelet aggregation by targeting the P2Y12 receptor. This combination is typically utilized in patients at high risk of atherosclerotic events, such as myocardial infarction or stroke, who require concurrent management of hypercholesterolemia and platelet-mediated thrombotic risk. As a generic product, it is marketed in various strengths, such as Atorgar-cv 40, which denotes the dosage of the statin component.

Brand names
Atorgar-CVAtorgar-cv 40Atorgar-cv40Atorgar-cv-40
Other names
atorvastatin + clopidogrel
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)P2Y12 (Purinergic P2Y12 receptor)

Beyond the preview

Go deeper on Atorgar-CV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atorgar-CV.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call